Yuanyuan He

Yuanyuan He

Auto-generated profile, based on publicly available information

Yuanyuan He

School of Biological and Pharmaceutical Engineering, Lanzhou Jiaotong University, Lanzhou 730070, China; Key Laboratory of Extreme Environmental Microbial Resources and Engineering of Gansu Province, Lanzhou 730070, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in Disease Markers
Verified
Journal Article
Open access
PDF file
WKWeihao Kong
Weihao Kong
YHYuanyuan He
Yuanyuan He
HBHuarui Bao
Huarui Bao
WZWenlong Zhang
Wenlong Zhang
XWXingyu Wang
Xingyu Wang
Background. Acute pancreatitis (AP) is a life-threatening disease caused by a variety of factors, and once it progresses to severe acute pancreatitis, the prognosis is poor. The purpose of this study was to investigate the diagnostic value of the neutrophil-lymphocyte ratio (NLR) for predicting the severity of acute pancreatitis. Materials and Methods. We searched the databases of PubMed, EMBASE, Web of Science, and Cochrane Library to identify eligible studies using the NLR to predict the severity of AP. The sensitivity (SEN), specificity (SPE), negative likelihood ratio (NLR), positive likelihood ratio (PLR), diagnostic odds ratio (DOR), and area under the receiver operating characteristic curve (AUC) were combined using a bivariate mixed model. Results. A total of 10 articles containing 394 cases and 1319 controls were included in the study. The combined SEN, SPE, NLR, PLR, DOR, and AUC are 79% (73%-84%), 71% (59%-80%), 0.30 (0.21-0.41), 2.7 (1.8-4.0), 9 (5-18), and 0.82 (0.78-0.85), respectively. Conclusions. NLR has a moderately high diagnostic value in predicting the severity of acute pancreatitis.

16 July 2022 in Science of The Total Environment
Verified
Journal Article
Closed access
YHYanli Huo
Yanli Huo
JMJiarun Mo
Jiarun Mo
YHYuanyuan He
Yuanyuan He
GTGratien Twagirayezu
Gratien Twagirayezu
LXLingui Xue
Lingui Xue

23 March 2018 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LYLin Yang
Lin Yang
ZWZHOU WAN
ZHOU WAN
YHYuanyuan He
Yuanyuan He
SLSumei Li
Sumei Li
YCYan Chen
Yan Chen
ZZZhimin Zhai
Zhimin Zhai
Keywords Type 2 diabetes; insulin intensive therapy; MCP-1; NF-κB

29 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
YHYuanyuan He
Yuanyuan He
XBXiaojie Bai
Xiaojie Bai
TZTiantian Zhu
Tiantian Zhu
JHJialin Huang
Jialin Huang
HZHong Zhang
Hong Zhang
Background Covid-19 became a global pandemic in 2019. Studies have shown that coronavirus can cause neurological symptoms, but clinical studies on its neurological symptoms are limited. In this meta-analysis, we aim to gather and discuss COVID-19 various neurological symptoms of infection, and to assess the prevalence of each of the nervous system symptoms, and characterized by neurological in-depth discussions of nervous system damage mechanism, biomarkers and inspection methods, recovery and prognosis, and provide the research behind the potential target and direction. Methods We systematically searched all published English literature related to the neurological manifestations of COVID-19 from January 1, 2020 to November 20, 2020 in Pubmed, Embase, and Cochrane library.The keywords used were COVID-19 and terminology related to nervous system performance.All included studies were selected by two independent reviewers using EndNote and NoteExpress software, any disagreement was resolved by consensus or by a third reviewer, and the selected data was then collected for meta-analysis using a random-effects model. Results A total of 62 articles (n =32729) were included in the study, and the meta-analysis showed that the most common neurological manifestations of COVID-19 were altered mental status (39% ; 95% CI 0.17-0.64 ; I 2 98.59%), encephalopathy (37% ; 95% CI 0.17-0.60 ; I 2 97.36%), myalgia(31% ; 95% CI 0.25-0.38; I 2 98.79%), headache(30% ; 95% CI 0.22-0.37; I 2 99.28%), smell impairment(28% ; 95% CI 99.57% ; I 2 0.17-0.39), taste dysfunction (27% ; 95% CI 0.18 -0.38 ; I 2 99.35%), acute ischemic stroke (23% ; 95% CI 0.06-0.47 ; I 2 99.30%), alteration of consciousness(17% ; 95% CI 0.06-0.31 ; I 2 96.78%), dizziness (10% ; 95% CI 0.06-0.15; I 2 95.30%), intracerebral haemorrhage (7% ; 95% CI 0.02-0.14 ; I 2 93.64%), vision impairment(5% ; 95% CI 0.02-0.10 ; I 2 92.73%), seizure(2% ; 95% CI 0.01-0.04 ; I 2 84.67%). Conclusions Neurological symptoms are common and varied in Covid-19 infections, and a growing number of reports suggest that the prevalence of neurological symptoms may be increasing. In the future, the role of COVID-19 neurological symptoms in the progression of COVID-19 should be further studied, and its pathogenesis and assessment methods should be explored, so as to detect and treat early neurological complications of COVID-19 and reduce mortality.

1 October 2018 in Journal Of Hypertension
Verified
Journal Article
Closed access
YHYuanyuan He
Yuanyuan He
XYXiaoguang Yao
Xiaoguang Yao
NLNanfang Li
Nanfang Li
To investigate whether polymorphisms of the surfactant protein B (SP-B) gene are associated with or increase the susceptibility to the development of obstructive sleep apnea (OSA). A total of 345 subjects (169 severe OSA patients, 176 controls) who underwent polysomnography (PSG) were continuously recruited from the Hypertension Center of the People's Hospital of Xinjiang from April to December 2016. Three candidate single nucleotide polymorphisms (SNPs) of the SP-B gene (rs1130866, rs2077079 and rs3024791) were selected and the genotype identification were determined by Kompetitive Allele Specifc PCR genotyping system. The frequencies of rs1130866 genotypes CC, CT and TT were 60.87%, 32.3% and 6.83% in severe OSA group, and 42.35%, 49.41% and 8.24% in the non-OSA group respectively. The genotype distributions of 3 polymorphisms in additive, allele and recessive model showed statistically significant difference between severe OSA and non-OSA group (P < 0.05). After adjustment of age, gender, BMI, smoking and alcohol history, multivariate linear regression showed that genotype CC of rs1130866 contributed as risk factor to OSA (OR = 2.885, 95%CI: 1.657–5.023, P < 0. 001). However, the frequencies of polymorphism of rs2077079 and rs3024791 showed no significant difference between the two groups (P > 0.05). The polymorphism (rs1130866) in SP-B gene potentially involved in the process of the loss of a potential N-linked, amino-terminus glycosylation site of pro-SP-B and may be related to OSA by the surfactant dysfunction in severe OSA subjects.